For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio
Shots:
- Biogen acquiring HI-Bio to advance felzartamab & HI-Bio’s pipeline using its global development & commercialization knowledge in rare diseases & scientific immunology expertise. It aims to keep HI-Bio's expertise to establish a San Francisco Bay Area team for immune-mediated diseases
- HI-Bio will receive $1.15B upfront & $650M development milestone for felzartamab (totalling $1.8B); Expected to conclude in Q3’24
- The acquisition adds felzartamab (P-II trials in PMN & AMR, and IgAN; planned P-III studies for same), izastobart (anti-C5aR1 Ab) for complement-mediated diseases, and discovery stage mast cell programs for immune-mediated diseases to Biogen’s portfolio. HI-Bio to present complete P-II AMR & interim IgAN data at ERA 2024
Ref: Biosciences | Image: Biosciences
Related News:- HI-Bio Reports P-II (M-PLACE) and (NewPLACE) Studies Results of Felzartamab to Treat Primary Membranous Nephropathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
